• A
  • |
  • A
  • Text size

Names Under Consideration

USAN Council's statement on the use of USAN as domain names:

A name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names Web site, shall be the effective equivalent of an intellectual property right on the part of the relevant entities.

Comments or protests should be addressed to Stephanie Shubat, USAN Program Director, American Medical Association, 330 North Wabash Avenue, Suite 39300, Chicago, Ill. 60611, or sent via email to USAN@ama-assn.org.

The following list of names for the drugs described are "under consideration" by the USAN Council:

November 2014

burisumab treatment of X-linked hypophosphatemia
flortaucipir brain diagnostic imaging agent
flortaupazine brain diagnostic imaging agent
padacitinib treatment of antineoplastic

October 2014

bertalzumab treatment of amyloidosis
domeglivant treatment of diabetes

September 2014

fexapotide treatment of prostate cancer
ivoponetide reduction in neuropathic pain
ruzasvir treatment of hepatitis C